William E Gillanders

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Metastatic Breast Cancer

Sentinel Lymph Node

Prognostic Factors

Top Venues

NPJ breast cancer

The Journal of experimental medicine

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Nadezhda V Terekhanova, Alla Karpova, Wen-Wei Liang, Alexander Strzalkowski, Siqi Chen, Yize Li, Austin N Southard-Smith, Michael D Iglesia, Michael C Wendl, Reyka G Jayasinghe, Jingxian Liu, Yizhe Song, Song Cao, Andrew Houston, Xiuting Liu, Matthew A Wyczalkowski, Rita Jui-Hsien Lu, Wagma Caravan, Andrew Shinkle, Nataly Naser Al Deen, John M Herndon, Jacqueline Mudd, Cong Ma, Hirak Sarkar, Kazuhito Sato, Omar M Ibrahim, Chia-Kuei Mo, Sara E Chasnoff, Eduard Porta-Pardo, Jason M Held, Russell Pachynski, Julie K Schwarz, William E Gillanders, Albert H Kim, Ravi Vij, John F Dipersio, Sidharth V Puram, Milan G Chheda, Katherine C Fuh, David G DeNardo, Ryan C Fields, Feng Chen, Benjamin J Raphael, Li Ding
Epigenetic regulation during cancer transitions across 11 tumour types. Nature (2023)
Sunkyung Kim, Jing Chen, Suin Jo, Feiya Ou, Stephen T Ferris, Tian-Tian Liu, Ray A Ohara, David A Anderson, Renee Wu, Michael Y Chen, William E Gillanders, William E Gillanders, Theresa L Murphy, Kenneth M Murphy
IL-6 selectively suppresses cDC1 specification via C/EBPβ. The Journal of experimental medicine 220 (10) (2023)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam M Brufsky, E Claire Dees, Cesar A Santa-Maria, Caitriona Cahir, Jeremy Force, Alvaro Moreno-Aspitia, John M Herndon, Madelyn Carmody, Sherri R Davies, Sarah Larson, Kathleen L Pfaff, Stephanie M Jones, Jason L Weirather, Anita Giobbie-Hurder, Scott J Rodig, Zheng Liu, Ian S Hagemann, Elad Sharon, William E Gillanders
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ breast cancer 8 (1) (2022)
Aubriana M McEvoy, Steven Poplack, Katelin Nickel, Margaret A Olsen, Foluso Ademuyiwa, Imran Zoberi, Elizabeth Odom, Jennifer Yu, Su-Hsin Chang, William E Gillanders
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound. Breast cancer research and treatment 183 (2) (2020)